Want to see FR:DIM full AI Analyst Report?
DIM Stock Chart & Stats
€167.30
-€3.70(-2.21%)
At close: 4:00 PM EDT
€167.30
-€3.70(-2.21%)
Day’s Range― - ―
52-Week Range€150.00 - €224.00
Previous CloseN/A
Volume20.49K
Average Volume (3M)78.09K
Market Cap
€18.83B
Enterprise Value€19.88K
Total Cash (Recent Filing)€203.90M
Total Debt (Recent Filing)€2.40B
Price to Earnings (P/E)64.1
Beta1.48
Next Earnings
Oct 22, 2026EPS Estimate
1.19Next Dividend Ex-DateN/A
Dividend Yield0.36%
Share Statistics
EPS (TTM)3.02
Shares Outstanding97,330,410
10 Day Avg. Volume78,938
30 Day Avg. Volume78,094
Financial Highlights & Ratios
PEG Ratio1.51
Price to Book (P/B)5.00
Price to Sales (P/S)6.89
P/FCF Ratio140.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€233.33Price Target Upside39.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)5
Revenue Forecast (FY)€3.13B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables ModelRecurring consumables create repeat revenue after equipment is installed, supporting customer retention and improving revenue visibility as biopharma production scales.
Revenue RecoveryThe strong revenue rebound indicates recovering demand across bioprocessing markets and provides operating scale that could support further earnings improvement as utilization normalizes.
Improved LeverageLower leverage and a larger equity base improve financial flexibility, reduce balance-sheet pressure and give the company greater capacity to support investment through the recovery.
Bears Say
Margins Remain Below Peak LevelsRevenue recovery has not yet restored historical profitability, leaving earnings more dependent on volume growth and making the durability of margin improvement an important execution risk.
Weak Free Cash Flow ConversionLow conversion of accounting profit into free cash flow limits internally funded investment and shareholder returns, while inconsistent cash generation can constrain flexibility during demand cycles.
Exposure To Biopharma Investment CyclesDemand depends partly on customers' capital programs and clinical-to-commercial progress, creating exposure to delayed facility spending, uneven production volumes and slower biopharma development cycles.
Sartorius Stedim Biotech News
DIM FAQ
What was Sartorius Stedim Biotech’s price range in the past 12 months?
Sartorius Stedim Biotech lowest stock price was €150.00 and its highest was €224.00 in the past 12 months.
What is Sartorius Stedim Biotech’s market cap?
Sartorius Stedim Biotech’s market cap is €18.83B.
When is Sartorius Stedim Biotech’s upcoming earnings report date?
Sartorius Stedim Biotech’s upcoming earnings report date is Oct 22, 2026 which is in 59 days.
How were Sartorius Stedim Biotech’s earnings last quarter?
Sartorius Stedim Biotech released its earnings results on Jul 23, 2026. The company reported €1.25 earnings per share for the quarter, missing the consensus estimate of €1.263 by -€0.013.
Is Sartorius Stedim Biotech overvalued?
According to Wall Street analysts Sartorius Stedim Biotech’s price is currently Undervalued.
Does Sartorius Stedim Biotech pay dividends?
Sartorius Stedim Biotech pays a Annually dividend of €0.69 which represents an annual dividend yield of 0.36%. See more information on Sartorius Stedim Biotech dividends here
What is Sartorius Stedim Biotech’s EPS estimate?
Sartorius Stedim Biotech’s EPS estimate is 1.19.
How many shares outstanding does Sartorius Stedim Biotech have?
Sartorius Stedim Biotech has 97,330,410 shares outstanding.
What happened to Sartorius Stedim Biotech’s price movement after its last earnings report?
Sartorius Stedim Biotech reported an EPS of €1.25 in its last earnings report, missing expectations of €1.263. Following the earnings report the stock price went down -6.446%.
Which hedge fund is a major shareholder of Sartorius Stedim Biotech?
Currently, no hedge funds are holding shares in FR:DIM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sartorius Stedim Biotech
Sartorius Stedim Biotech S.A., a global entity and a subsidiary of Sartorius AG, delivers critical instruments, consumables, and services tailored for the biopharmaceutical industry. Their extensive product portfolio includes fundamental components like cell lines, cell culture media, and bioreactors, alongside comprehensive solutions for separation, purification, and concentration processes. They also provide specialized systems for the safe storage and transport of biological intermediates and finished products. For advanced applications, particularly in cell and gene therapy, the company offers both single-use and reusable hollow-fiber membrane devices and presterilized assemblies. Beyond physical products, their service offerings cover vital bioprocessing steps such as cell cultivation, fermentation, filtration, purification, and fluid management, in addition to cell harvesting and broader solutions for intensified bioprocesses. Furthermore, Sartorius Stedim Biotech provides advanced data analytics software designed to model and optimize biopharmaceutical development and production workflows. Serving a diverse customer base, including pharmaceutical, food, and chemical manufacturers, as well as research and development laboratories, the company was founded in 1870 and operates from its headquarters in Aubagne, France.
DIM Stock 12 Month Forecast
Average Price Target
€233.33
▲(39.47% Upside)